The prior say-on-pay vote received 96.5% support, well above the 70% threshold that would require visible action, and the compensation structure passes key pay-mix tests — the proxy states that 60% or more of total compensation for the CEO and other named executives was delivered through variable pay in 2025, meeting the policy's minimum 50-60% variable pay requirement. The CEO's total compensation of approximately $8.25 million is within a plausible range for a specialty chemicals CEO at a $1.8 billion company, and the long-term incentive plan uses a mix of relative total shareholder return, revenue growth, and earnings-per-share growth metrics over a multi-year period, which are meaningful performance conditions rather than time-vesting alone. While the company's stock performance has been poor relative to peers, the variable pay structure appropriately reflected that — operating income came in at 87% of target, resulting in a reduced annual cash bonus payout of roughly 67.5% of the financial performance component — demonstrating that the incentive plan is functioning as designed and penalizing executives when results fall short.

PwC has audited Innospec since May 2019 — roughly seven years — which is well below the 25-year threshold that would raise independence concerns. Non-audit fees of $34,000 represent less than 2% of audit fees of $3,050,000, far below the 50% level that would trigger a concern. PwC is a Big 4 firm appropriate for a $1.8 billion market-cap company, and no material restatements were identified.